MedTrace Logo

Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer

NCT02577341 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2021-02-11

No results posted yet for this study

Summary

This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.

Conditions

  • Non-small-cell Lung Cancer

Interventions

DRUG

Nimotuzumab

Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.

DRUG

docetaxel and cisplatin

Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy

RADIATION

daily RT to the chest

Patients received daily RT to the chest

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Hui Liu, Professor · Sun yat-sen universtiy cancer center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2020-06-30
Completion
2020-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02577341 on ClinicalTrials.gov